Clinical Trials in Germany / NCT05373719
Active, not recruiting
Observational
Observational Study in Patients With Cyclin-dependent Kinase-like 5 Deficiency Disorder
NCT05373719 · tracked via the Priya Life Science Germany tracker
Condition(s) studied
Cyclin-Dependent Kinase-Like 5 Deficiency Disorder
Investigational drug(s) / intervention(s)
No intervention; observational
No intervention; observational: No intervention; observational
Study summary
Observational, noninterventional, 3-year study to examine the presence of detectable differences in neurocognitive, developmental, motor, neurophysiologic, and quality of life measures over time in patients with cyclin-dependent kinase-like 5 deficiency disorder.
Eligibility
Inclusion Criteria:
1. Documented diagnosis of Cyclin-dependent Kinase-like 5 (CDKL5) deficiency disorder with pathogenic or likely pathogenic of CDKL5 variants
2. Ages newborn to 55 years old
3. Parent/Caregiver who is willing and capable of providing written informed consent
4. Parent/caregiver lives with or has daily contact with study participant and able to provide consistent information across the study
Exclusion Criteria:
1. Any clinically significant neurocognitive deficit not attributable to Cyclin-dependent Kinase-like 5 (CDKL5) deficiency disorder or a secondary cause that may, in the opinion of the investigator, confound interpretation of study results (e.g., extreme prematurity, other genetic variants, unclassified CDKL5 variant, abnormal brain imaging, imaging and/or injury not otherwise attributable to CDD).
2. Any condition that, in the opinion of the investigator, would put the patient at undue risk or make it unsafe for the patient to participate
3. Any condition which would make the individual or the caregiver, in the opinion of the investigator, unsuitable for the study
Primary outcome measure(s)
- Bayley Scale of Infant and Toddler Development, Fourth Edition (BSID-4) — Baseline
Suitability of this cognition and global development scale in CDD will be assessed based on the number of tests completed, ceiling/floor effect and variance estimate. - Vineland 3 — Baseline
Suitability of this adaptive behavior scale in CDD will be assessed based on the number of tests completed, ceiling/floor effect and variance estimate. - Gross Motor Function Measure (GMFM) — Baseline
Suitability of this motor function scale in CDD will be assessed based on the number of tests completed, ceiling/floor effect and variance estimate. - Sleep Disturbance Scale for Children (SDSC) — Baseline
Suitability of this sleep quality scale in CDD will be assessed based on the number of tests completed, ceiling/floor effect and variance estimate.
Trial sites (23)
| Facility | City | Region | Status |
|---|---|---|---|
| UCLA Mattel Children's Hospital | Los Angeles | California | |
| Children's Hospital Colorado | Aurora | Colorado | |
| Center for Rare Neurological Diseases | Norcross | Georgia | |
| Boston Children's Hospital | Boston | Massachusetts | |
| New York University | New York | New York | |
| Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio | |
| The Cleveland Clinic | Cleveland | Ohio | |
| Childrens Hospital of Philadlephia Division of Neurology | Philadelphia | Pennsylvania | |
| Baylor College of Medicine | Houston | Texas | |
| Alberta Children's Hospital, Pediatric Epilepsy and Child Neurology | Calgary | Canada | |
| The Hospital of Sick Children | Toronto | Canada | |
| Hopital Necker- Enfants Malades | Paris | France | |
| DRK Berlin - Epilepsiezentrum und Neuropädiatrie | Berlin | Germany | |
| Schön Klinik Vogtareuth | Vogtareuth | Germany | |
| Azienda Ospedaliero-Universitaria Meyer | Florence | Italy | |
| Fondazione Policlinico Universitario A Gemelli, IRCCS | Roma | Italy | |
| Ospedale Pediatrico Bambino Gesù | Rome | Italy | |
| Azienda Ospedaliera Universitaria Integrata di Verona | Verona | Italy | |
| Hospital Infantil Universitario Niño Jesús | Madrid | Spain | |
| Ruber Internacional Hospital | Madrid | Spain | |
| Hospital UniversitarioVithas Madrid | Madrid | Spain | |
| Ruber Internacional Hospital | Madrid | Spain | |
| Mediclinic | Dubai | United Arab Emirates |
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05373719 on ClinicalTrials.gov ↗ ← All trials in Germany